论文部分内容阅读
目的:比较多沙唑嗪联合托特罗定与坦索罗辛联合托特罗定治疗良性前列腺增生(BPH)下尿路症状(LUTS)的尿流动力学变化的研究。方法:选取诊断明确的BPH患者50例,采用随机非双盲方法平均分为A、B两组,A组患者服用多沙唑嗪联合酒石酸托特罗定缓释剂、B组患者服用坦索罗辛联合酒石酸托特罗定缓释剂联合治疗12周,于治疗前后对潴尿期与排尿期的相关尿流动力学指标,如最大尿流率(Qmax)、膀胱剩余尿量、最大膀胱容量、排尿开始时膀胱压、膀胱顺应性等进行比较。结果:两组在治疗前的各项指标无统计学意义。服药治疗12周后,两组Qmax、排尿开始时膀胱压、膀胱顺应性均较治疗前有明显改善。而剩余尿量和最大膀胱容量较治疗前无明显变化。治疗后两组间比较,A组Qmax、排尿开始时膀胱压、膀胱顺应性均优于B组(P<0.05),而两治疗组之间的剩余尿量及最大膀胱容量差异无统计学意义(P>0.05)。结论:α受体阻滞剂联合M受体阻滞剂治疗BPH能明显提高Qmax,降低排尿开始时膀胱压力,改善膀胱顺应性,且多沙唑嗪联合应用M受体阻滞剂优于坦索罗辛联合应用M受体阻滞剂。
OBJECTIVE: To compare urodynamic changes of urinary tract symptoms (LUTS) with doxazosin plus tolterodine and tamsulosin in combination with tolterodine in the treatment of benign prostatic hyperplasia (BPH). Methods: Fifty BPH patients with definite diagnosis were randomly divided into A and B groups by random non-double-blind method. Patients in group A received doxorubicin combined with tolterodine tartrate sustained-release agent and patients in group B received tamsulosin Rosein combined with tolterodine tartrate sustained-release agent combination therapy for 12 weeks, before and after treatment of urinary retention and urinary phase urodynamic indicators, such as the maximum flow rate (Qmax), bladder residual urine volume, maximum bladder capacity , Urinary bladder pressure at the beginning, bladder compliance and so on. Results: There was no significant difference between the two groups before treatment. After 12 weeks of treatment, the Qmax of both groups, bladder pressure at the beginning of urination, and bladder compliance were significantly improved than those before treatment. The remaining urine volume and maximum bladder capacity compared with no significant change before treatment. After treatment, Qmax in group A was significantly higher than that in group B (P <0.05), while bladder pressure and bladder compliance at the beginning of urination showed no significant difference between the two groups (P> 0.05). Conclusion: The treatment of BPH with α-blocker and M-blocker can significantly increase Qmax, reduce the bladder pressure at the beginning of urination and improve bladder compliance, and the combination of doxazosin and M receptor blocker is better than that of Tan Sorosin combined M receptor blockers.